Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12273573 | 0.98 | OPRM1 (0.61) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL28305036 | 0.94 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL12273671 | 0.94 | OPRM1 (0.56) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Hydrochloric Acid SCHEMBL12273066 | 0.92 | OPRM1 (0.58) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL22992467 | 0.90 | OPRM1 (0.52) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL28523959 | 0.86 | OPRM1 (0.48) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL10318609 | 0.85 | OPRM1 (0.60) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL22992533 | 0.84 | OPRM1 (0.47) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL24220122 | 0.83 | OPRM1 (0.76) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1510 | 0.83 | OPRM1 (0.58) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022148196-A1 | MULTIKINASE INHIBITOR AND USE THEREOF | 苏州安睿药业有限公司 | 2022-07-14 | — | — | WO | disclosed |
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-21 | — | — | US | disclosed |
| US-20210220326-A1 | Compounds and Methods for Inhibiting CPY26 Enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2021-07-22 | — | — | US | disclosed |
| US-10874634-B2 | Compounds and methods for inhibiting CYP26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2020-12-29 | — | — | US | disclosed |
| EP-2504314-B1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| CN-102648178-B | Quinazoline derivatives | MERCK PATENT GMBH | 2015-01-07 | — | — | CN | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | disclosed |
| CN-102648178-A | Quinazoline derivatives | MERCK PATENT GMBH | 2012-08-22 | — | — | CN | disclosed |
| WO-2011060873-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061760-A1 | NOVEL ANTITHROMBOTIC AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874634-B2 | Compounds and methods for inhibiting CYP26 enzymes | CYP26B1, CYP2A6, CYP26A1 | OPRM1 3780/4885OPRD1 2982/4885OPRK1 2591/4885 |
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | CYP2A6, CYP27A1, CYP26B1 | OPRM1 4442/4885OPRD1 4159/4885OPRK1 3760/4885 |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90B1 | OPRM1 2492/4885OPRD1 1697/4885OPRK1 1444/4885 |
| US-20210220326-A1 | Compounds and Methods for Inhibiting CPY26 Enzymes | CYP2A6, CYP27A1, CYP26B1 | OPRM1 4340/4885OPRD1 4179/4885OPRK1 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.